Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 7, 2025
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
August 7, 2025
Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025 Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independent Data Safety Monitoring Committee completed fourth …
Stereotaxis Reports 2025 Second Quarter Financial Results
GlobeNewswire
·
August 7, 2025
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are …
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug …
Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025
GlobeNewswire
·
August 7, 2025
PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, …
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial extension …
Apyx Medical Corporation Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025 Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial procedures Based …
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
GlobeNewswire
·
August 7, 2025
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial of claseprubart …
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 …
Ascendis Pharma Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
– Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® ( …
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 7, 2025
TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth …
Teknova Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- …
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
GlobeNewswire
·
August 7, 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 7, 2025
Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years. Received the …
Nephros Announces Strong Second Quarter Financial Results
GlobeNewswire
·
August 7, 2025
SOUTH ORANGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June …
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date Primary Results from MAPLE-HCM to be Presented in a Hot Line Session at …
MEDIROM Joins the World Network, Embracing Next-Generation Proof of Human Concept Led by ChatGPT Creator Sam Altman
GlobeNewswire
·
August 7, 2025
Creating new social infrastructure in collaboration with Hakuhodo To promote the spread of World ID in Japan, Verification Device“Orb”will be installed in 100 Re.Ra.Ku relaxation salons. TOKYO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare …
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
GlobeNewswire
·
August 7, 2025
- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START’ study of …
Helios Alliance Announces Project Persevere to Combat Opioid Crisis in Mobile, Alabama
GlobeNewswire
·
August 7, 2025
Mobile, Alabama, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Helios Alliance, in partnership with the City of Mobile and Mobile County, recently unveiled Project Persevere, a comprehensive communications campaign aimed at reducing the stigma surrounding opioid …
Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités
GlobeNewswire
·
August 7, 2025
- Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 % et un taux de survie globale de 79 % à 12 mois - D’après …
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung
GlobeNewswire
·
August 7, 2025
– Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine Ansprechrate von 63 % bei 43 auswertbaren Patienten und …